The c-Met-directed antibody-drug conjugate telisotuzumab vedotin demonstrated sturdy responses and an appropriate security profile in sufferers of Asian race with c-Met protein-overexpressing, epidermal development issue receptor (EGFR) wildtype (WT), domestically superior/metastatic nonsquamous non-small cell lung most cancers (NSCLC), based on analysis introduced as we speak on the Worldwide Affiliation for the Examine of Lung Most cancers’s 2024 World Convention on Lung Most cancers.
The c-Met protein is a receptor tyrosine kinase that mediates cell proliferation, survival, and angiogenesis, and could be dysregulated in sufferers with NSCLC. Roughly 25% of sufferers with EGFR WT nonsquamous NSCLC have tumors that overexpress c-Met protein, which can be related to poor survival.
Dr. Hidehito Horinouchi, of the Nationwide Most cancers Heart Hospital in Japan, participated within the LUMINOSITY section 2 (NCT03539536) scientific trial aiming to determine the c-Met protein-overexpressing NSCLC inhabitants finest suited to Teliso-V monotherapy and develop chosen teams for additional analysis.
For the needs of this research, the researchers outlined c-Met protein overexpression as higher than 25% tumor cells with greater than 3+ staining (excessive: ≥50% 3+; intermediate [int]: 25% to <50% 3+). Sufferers acquired 1.9 mg/kg intravenously each two weeks and the first endpoint was Total Response Charge (ORR).
In whole, 172 sufferers with c-Met protein-OE EGFR WT nonsquamous NSCLC acquired no less than one dose of Teliso-V, 57 of whom had been Asian. A complete of 48 Asian sufferers (c-Met excessive, n=26; c-Met intermediate, n=22) had been evaluable for efficacy.
Median age in sufferers of Asian race was 65 years (vary 47-82), 71% had been male, and 67% had ECOG PS ≥1. Total, 92% acquired prior platinum remedy and 77% had prior immune checkpoint inhibitor remedy. For the Asian inhabitants, the ORR was 46.2% (c-Met excessive), 22.7% (c-Met intermediate), and 35.4% (general). Median period of response was 6.9 months (c-Met excessive), 8.3 months (c-Met intermediate), and 6.9 months (general). The most typical hostile occasions had been hypoalbuminemia (32%), peripheral sensory neuropathy (23%), and pneumonia (21%).
Compelling and sturdy responses had been noticed in sufferers of Asian race with c-Met protein-OE nonsquamous EGFR WT NSCLC, particularly in sufferers with c-Met excessive; these outcomes are just like the general inhabitants.”
Dr. Hidehito Horinouchi, Nationwide Most cancers Heart Hospital, Japan
He added that Teliso-V had an appropriate security profile that was clinically manageable.
Teliso-V is being evaluated as a monotherapy in sufferers with beforehand handled c-Met overexpressing EGFR wild kind nonsquamous NSCLC within the randomized Part 3 research TeliMET NSCLC-01 (NCT04928846), which is presently enrolling.
Supply:
Worldwide Affiliation for the Examine of Lung Most cancers
